Glucagonoma surgery

Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma surgery

CDC on Glucagonoma surgery

Glucagonoma surgery in the news

Blogs on Glucagonoma surgery

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis.[1]

Surgery

Surgery is the mainstay of treatment for glucagonoma. The feasibility of surgery depends on the stage of glucagonoma at diagnosis.[1][2]

  • Single, small lesion in head or tail of pancreas:
  • Enucleation, if feasible
  • Large lesion in the head of the pancreas that is not amenable to enucleation:
  • Pancreaticoduodenectomy
  • Single, large lesion in body/tail:
  • Distal pancreatectomy
  • Multiple lesions:
  • Enucleation, if feasible
  • Resect body and tail otherwise
  • Resect when possible
  • Consider radiofrequency or cryosurgical ablation, if not resectable
  • Unresectable disease:
  • Combination chemotherapy
  • Somatostatin analogue therapy. Necrotizing erythema of glucagonoma may be relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week

References

  1. 1.0 1.1 Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS (2004). "Clinical experience in diagnosis and treatment of glucagonoma syndrome". Hepatobiliary Pancreat Dis Int. 3 (3): 473–5. PMID 15313692.
  2. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors). National Cancer Institute. http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq#section/_88


Template:WikiDoc Sources